003 BR Feb 2020

Combining RCTs and RWE studies to alter the regulatory approval process

Hybridisation of RCTs and RWE studies reinforce the benefits of both, while reducing the limitations of traditional study formats The potential of real-world data that provides adequate scientific evidence for regulatory decision-making is being realised Innovative study designs must be developed to unlock this potential Click here to learn more About SVMPharma SVMPharma is an innovative strategic […]

Read More
001 LN Feb 2020

Real-world data provides the opportunity to enhance regulatory decisions for new drugs

Real-world data and evidence provide valuable performance data on a post-approval drug to create a comprehensive clinical snapshot This can later support regulatory and reimbursement decisions and clinical guidelines More and more stakeholders in the pharmaceutical pipeline are recognising the value of real-world data Click here to learn more About SVMPharma SVMPharma is an innovative strategic consultancy, […]

Read More
001 VN Feb 2020

Cancer Electronic Prescribing Records – Real-world Data

  Electronic prescribing records, or EPRs, are a rich untapped source of real-world evidence SVMPharma’s unique EPR real-world studies are one step ahead of the Systemic Anti-Cancer Therapy (SACT) data set Click here to learn more About SVMPharma SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma […]

Read More